tiprankstipranks
Advertisement
Advertisement

RYTM Stock Latest News

EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
Company AnnouncementsEMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
7d ago
RYTM
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
8d ago
RYTM
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
8d ago
RYTM
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
8d ago
RYTM
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
8d ago
RYTM
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
PremiumRatingsImcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
8d ago
RYTM
Rhythm Pharmaceuticals Earnings Call Signals Momentum
Premium
Company Announcements
Rhythm Pharmaceuticals Earnings Call Signals Momentum
8d ago
RYTM
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
Premium
Company Announcements
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
9d ago
8K
RYTM
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
PremiumThe Fly
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
9d ago
RYTM
RYTM Earnings this Week: How Will it Perform?
PremiumPre-Earnings
RYTM Earnings this Week: How Will it Perform?
11d ago
RYTM
Analyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target
PremiumRatings
Analyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target
17d ago
RYTM
Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan
PremiumThe Fly
Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan
17d ago
RYTM
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks NewswireWhat the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
22d ago
PTN
CRNX
Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM
Premium
Company Announcements
Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM
29d ago
RYTM
Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital
1M ago
RYTM
Rhythm Pharmaceuticals Stockholders Back Board, Governance Proposals
PremiumCompany Announcements
Rhythm Pharmaceuticals Stockholders Back Board, Governance Proposals
2M ago
8K
RYTM
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
PremiumTipRanks Newswire
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
2M ago
LLY
NVO
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
PremiumRatings
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
2M ago
RYTM
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
2M ago
RYTM
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials
PremiumCompany AnnouncementsRhythm Showcases Positive Setmelanotide Data Across Obesity Trials
2M ago
8K
RYTM
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
2M ago
RYTM
Rhythm Pharmaceuticals: Phase 2 PWS Data Strengthen Outlook as Buy Rating and $130 Price Target Are Reaffirmed
Premium
Ratings
Rhythm Pharmaceuticals: Phase 2 PWS Data Strengthen Outlook as Buy Rating and $130 Price Target Are Reaffirmed
2M ago
RYTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >